Literature DB >> 20003619

Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.

Cedric Mombereau1, Tamar L Gur, Jennifer Onksen, Julie A Blendy.   

Abstract

Clinically, SSRIs are widely prescribed in the treatment of several anxiety disorders, although very few pre-clinical studies have observed a beneficial effect of this class of drugs in animal models of anxiety. Furthermore, the biphasic pattern observed clinically, an exacerbation of anxiety followed by beneficial effects, is rarely observed in animal studies. In the present study we document this clinical phenomenon in several behavioural paradigms. While a single injection of citalopram induced anxiogenic effects, three administrations of citalopram were sufficient to elicit anxiolytic effects. Congruent with these data, we observed that short-term repeated administration of citalopram was accompanied by increased activation of cAMP response element-binding protein (CREB) in the hippocampus and desensitization of 5-HT1A receptors, two phenomena well associated with chronic rather than acute actions of antidepressants. Moreover, effects of citalopram were abolished in CREBalphaDelta mutant animals in the elevated zero maze (EZM) and tail suspension test (TST), but not in novelty-induced hypophagia (NIH). Further, the desensitization of 5-HT1A receptors elicited by citalopram was not affected by CREB deficiency. The significance of the EZM and TST paradigms in predicting therapeutic efficacy is well known while effects in NIH and 5-HT1A sensitization are less well-established. These data demonstrate that behavioural responses to citalopram are dependent on the frequency of its administration, and that these responses are differentially dependent on CREB function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20003619      PMCID: PMC3646514          DOI: 10.1017/S1461145709990630

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  60 in total

1.  Open fluoxetine treatment of mixed anxiety disorders in children and adolescents.

Authors:  J M Fairbanks; D S Pine; N K Tancer; E S Dummit; L M Kentgen; J Martin; B K Asche; R G Klein
Journal:  J Child Adolesc Psychopharmacol       Date:  1997       Impact factor: 2.576

2.  Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents.

Authors:  G Griebel; J L Moreau; F Jenck; R Misslin; J R Martin
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

Review 3.  Current advances and trends in the treatment of depression.

Authors:  P Blier; C de Montigny
Journal:  Trends Pharmacol Sci       Date:  1994-07       Impact factor: 14.819

4.  Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine.

Authors:  E Le Poul; N Laaris; E Doucet; A M Laporte; M Hamon; L Lanfumey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

5.  Serotonin1A receptor activation by flesinoxan in humans. Body temperature and neuroendocrine responses.

Authors:  B Seletti; C Benkelfat; P Blier; L Annable; F Gilbert; C de Montigny
Journal:  Neuropsychopharmacology       Date:  1995-10       Impact factor: 7.853

6.  Identification of 5-hydroxytryptamine7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment.

Authors:  A J Sleight; C Carolo; N Petit; C Zwingelstein; A Bourson
Journal:  Mol Pharmacol       Date:  1995-01       Impact factor: 4.436

7.  Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus.

Authors:  M Nibuya; E J Nestler; R S Duman
Journal:  J Neurosci       Date:  1996-04-01       Impact factor: 6.167

8.  Activation of a mitogen-activated protein kinase (ERK2) by the 5-hydroxytryptamine1A receptor is sensitive not only to inhibitors of phosphatidylinositol 3-kinase, but to an inhibitor of phosphatidylcholine hydrolysis.

Authors:  D S Cowen; R S Sowers; D R Manning
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

9.  5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice.

Authors:  Y Ichimaru; T Egawa; A Sawa
Journal:  Jpn J Pharmacol       Date:  1995-05

10.  Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine.

Authors:  G Griebel; D C Blanchard; R S Agnes; R J Blanchard
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

View more
  19 in total

1.  Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.

Authors:  O J Onaolapo; T B Paul; A Y Onaolapo
Journal:  Metab Brain Dis       Date:  2017-05-15       Impact factor: 3.584

2.  Dorsal raphe neuroinflammation promotes dramatic behavioral stress dysregulation.

Authors:  Alexis R Howerton; Alison V Roland; Tracy L Bale
Journal:  J Neurosci       Date:  2014-05-21       Impact factor: 6.167

3.  Biphasic effects of selective serotonin reuptake inhibitors on anxiety: rapid reversal of escitalopram's anxiogenic effects in the novelty-induced hypophagia test in mice?

Authors:  Wouter Koek; Nathan C Mitchell; Lynette C Daws
Journal:  Behav Pharmacol       Date:  2018-06       Impact factor: 2.293

4.  Pharmacological modulation of stress-induced behavioral changes in the light/dark exploration test in male C57BL/6J mice.

Authors:  Jessica L Ihne; Paul J Fitzgerald; Kathryn R Hefner; Andrew Holmes
Journal:  Neuropharmacology       Date:  2011-09-02       Impact factor: 5.250

5.  Behavioral and activity assessment of laboratory mice (Mus musculus) after tail biopsy under isoflurane anesthesia.

Authors:  F Claire Hankenson; Gillian C Braden-Weiss; Julie A Blendy
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-09       Impact factor: 1.232

6.  Chronic modulation of serotonergic neurotransmission with sertraline attenuates the loudness dependence of the auditory evoked potential in healthy participants.

Authors:  Julian G Simmons; Pradeep J Nathan; Gregor Berger; Nicholas B Allen
Journal:  Psychopharmacology (Berl)       Date:  2011-04-05       Impact factor: 4.530

7.  CREB deletion increases resilience to stress and downregulates inflammatory gene expression in the hippocampus.

Authors:  Melissa T Manners; Julia K Brynildsen; Max Schechter; Xin Liu; Darrell Eacret; Julie A Blendy
Journal:  Brain Behav Immun       Date:  2019-06-27       Impact factor: 7.217

8.  Isobolographic analysis of the antidepressant interaction in two-drug combinations of citalopram, bupropion, and scopolamine in mice.

Authors:  Mohammad-Hossein Mohammadi-Mahdiabadi-Hasani; Mohaddeseh Ebrahimi-Ghiri; Fatemeh Khakpai; Mohammad-Reza Zarrindast
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-04-19       Impact factor: 3.000

9.  Increased hippocampal neurogenesis and accelerated response to antidepressants in mice with specific deletion of CREB in the hippocampus: role of cAMP response-element modulator τ.

Authors:  Brigitta B Gundersen; Lisa A Briand; Jennifer L Onksen; John Lelay; Klaus H Kaestner; Julie A Blendy
Journal:  J Neurosci       Date:  2013-08-21       Impact factor: 6.167

10.  Fetal brain 11β-hydroxysteroid dehydrogenase type 2 selectively determines programming of adult depressive-like behaviors and cognitive function, but not anxiety behaviors in male mice.

Authors:  Caitlin Wyrwoll; Marianne Keith; June Noble; Paula L Stevenson; Vincent Bombail; Sandra Crombie; Louise C Evans; Matthew A Bailey; Emma Wood; Jonathan R Seckl; Megan C Holmes
Journal:  Psychoneuroendocrinology       Date:  2015-05-18       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.